Cocrystal Pharma (COCP) CEO James Sapirstein files initial Form 3

Rhea-AI Filing Summary

Cocrystal Pharma, Inc. filed an initial ownership report on Form 3 for Chief Executive Officer James Sapirstein. This filing establishes his status as an insider but does not list any buy, sell, or derivative transactions, and shows no current holdings or option positions in the data provided.

Key Terms

Form 3, Chief Executive Officer, insider

3 terms

Form 3 regulatory

"filed an initial ownership report on Form 3 for Chief Executive Officer"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Chief Executive Officer financial

"filed an initial ownership report on Form 3 for Chief Executive Officer James Sapirstein"

A chief executive officer (CEO) is the top leader of a company, responsible for making major decisions, setting goals, and guiding the organization’s overall direction. Think of the CEO as the captain of a ship, steering it toward success. Investors pay close attention to the CEO because their leadership and strategy can significantly influence the company's performance and future growth.

insider regulatory

"This filing establishes his status as an insider but does not list any buy"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

SAPIRSTEIN JAMES

(Last) (First) (Middle)

4400 BISCAYNE BLVD.,

(Street)

MIAMI FLORIDA 33157

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/03/2026

3. Issuer Name and Ticker or Trading Symbol
Cocrystal Pharma, Inc. [ COCP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ James Sapirstein	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Cocrystal Pharma (COCP) Form 3 filing show for James Sapirstein?

The Form 3 filing shows that James Sapirstein is the Chief Executive Officer of Cocrystal Pharma and is now an SEC-reporting insider. The data provided does not include any reportable holdings or transactions in this initial statement.

Does the Cocrystal Pharma (COCP) Form 3 report any stock purchases or sales?

The Form 3 data shows no reported purchases or sales by James Sapirstein. All transaction counts, including buy, sell, and derivative exercises, are listed as zero in the transaction summary section.

Are there any derivative securities reported for James Sapirstein in the COCP Form 3?

The filing indicates no derivative securities for James Sapirstein. The derivative summary is empty and the transaction summary lists zero derivative transactions and zero shares from option or similar exercises.

What insider status does James Sapirstein hold at Cocrystal Pharma (COCP)?

James Sapirstein is identified as an officer of Cocrystal Pharma, specifically serving as Chief Executive Officer. This status subjects him to ongoing SEC reporting obligations for future changes in his beneficial ownership of company securities.

Do the footnotes in the Cocrystal Pharma (COCP) Form 3 change ownership interpretation?

The provided Form 3 data includes a null footnote entry, with no additional explanatory text. Based on this data, there are no disclosed special arrangements, entities, or voting and investment authority qualifiers affecting James Sapirstein’s insider status.